Julia Lainster

The approval of Guardant360 CDx as a companion diagnostic for AstraZeneca’s camizestrant marks the first time a liquid biopsy has been authorized for continuous monitoring of cancer evolution. This regulatory milestone fundamentally alters the management of advanced breast cancer by allowing

While immunotherapy was previously confined to treating advanced stages of the disease, new evidence shows its efficacy in earlier, resectable settings. Gastric cancer has long remained a formidable opponent within the global oncology landscape, currently ranking as the fifth most common cancer

The objective of deploying high-precision robotics in the operating room is to provide a level of accuracy that exceeds the natural physical limitations of the human hand. This pursuit of surgical excellence has catalyzed a global healthcare transformation, moving away from traditional invasive

Although lamotrigine is a staple treatment for bipolar disorder and epilepsy, it triggers a dangerous systemic immune response in approximately one out of every thousand patients. Known as Stevens-Johnson Syndrome, this reaction causes severe skin detachment and organ damage. For years, doctors

Novartis and Bristol Myers Squibb have inadvertently set a new precedent for transparency as they navigate the complex safety challenges of applying oncology tools to chronic autoimmune diseases. This strategic pivot reflects a broader industry realization that the risk-benefit calculus for

Data filtering initiatives, such as excluding eukaryotic viruses from training sets, represent the first steps in preventing AI models from learning how to design human pathogens. This protective measure is increasingly vital as the intersection of artificial intelligence and the life sciences

Under the leadership of Dr. Patrick Hwu, Moffitt Cancer Center is evolving into a facility that prioritizes the rapid translation of laboratory discoveries into clinical products for patient use. This strategic direction stems from a professional journey that began in the unlikely setting of St.

While complex genetic clusters were once thought to be the key to precision medicine, new analysis suggests that routine clinical data may be just as effective for drug selection. For decades, the management of Type 2 diabetes has relied on a rigid, standardized protocol where patients are moved

Phase I Pharmacokinetic studies cannot reach their primary endpoints until bioanalytical data is confirmed as valid across the newly integrated organizational framework. The clinical research landscape shifted significantly with the announcement of Fortrea’s acquisition of Worldwide Clinical

When the protein-processing machinery of the endoplasmic reticulum is overwhelmed by external stressors, it triggers a cascade of signaling pathways that culminate in programmed cell death. In the current landscape of 2026, oncology has moved decisively toward these types of organelle-specific